Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1800388rdf:typepubmed:Citationlld:pubmed
pubmed-article:1800388lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:1800388lifeskim:mentionsumls-concept:C0039373lld:lifeskim
pubmed-article:1800388lifeskim:mentionsumls-concept:C0340288lld:lifeskim
pubmed-article:1800388lifeskim:mentionsumls-concept:C1261322lld:lifeskim
pubmed-article:1800388lifeskim:mentionsumls-concept:C0178566lld:lifeskim
pubmed-article:1800388lifeskim:mentionsumls-concept:C0439583lld:lifeskim
pubmed-article:1800388lifeskim:mentionsumls-concept:C0302350lld:lifeskim
pubmed-article:1800388lifeskim:mentionsumls-concept:C0185125lld:lifeskim
pubmed-article:1800388lifeskim:mentionsumls-concept:C0694643lld:lifeskim
pubmed-article:1800388lifeskim:mentionsumls-concept:C0065961lld:lifeskim
pubmed-article:1800388pubmed:issue11lld:pubmed
pubmed-article:1800388pubmed:dateCreated1992-4-21lld:pubmed
pubmed-article:1800388pubmed:abstractText10 patients (6 females and 4 males with an average age of 75 years) with stable angina pectoris were treated transdermally with mepindolol in a balanced, randomized, controlled, crossover study to compare the anti-ischemic effects of 12-hour overnight, and 24-hour applications. The number of angina pectoris attacks, the oral nitrate consumption and the ischemic parameters in 24-hour ECG, i.e. episodes of manifest (MMI) and silent (SMI) myocardial ischemia, the total duration of ischemia and 24-hour heart rate profiles were investigated. Both application schemes showed typical systemic beta blocker effects in all patients and significant clinical efficacy. A dose/effect relationship and a time/effect relationship between the two different application schemes were demonstrated across all the parameters investigated. Systemic and local tolerance of the therapy was good. 2 patients showed transient, mild skin irritation, but only during one phase of the study. Premature discontinuation was not necessary in any cases. There were no relevant changes in the clinical-chemistry. The new therapeutic concept of 24-hour treatment for a. pectoris with 12-hour overnight transdermal applications showed both good clinical efficacy and a good safety profile.lld:pubmed
pubmed-article:1800388pubmed:languageenglld:pubmed
pubmed-article:1800388pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1800388pubmed:citationSubsetIMlld:pubmed
pubmed-article:1800388pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1800388pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1800388pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1800388pubmed:statusMEDLINElld:pubmed
pubmed-article:1800388pubmed:monthNovlld:pubmed
pubmed-article:1800388pubmed:issn0174-4879lld:pubmed
pubmed-article:1800388pubmed:authorpubmed-author:BonelliJJlld:pubmed
pubmed-article:1800388pubmed:authorpubmed-author:KirschPPlld:pubmed
pubmed-article:1800388pubmed:authorpubmed-author:LiedtkeR KRKlld:pubmed
pubmed-article:1800388pubmed:authorpubmed-author:GazoFFlld:pubmed
pubmed-article:1800388pubmed:issnTypePrintlld:pubmed
pubmed-article:1800388pubmed:volume29lld:pubmed
pubmed-article:1800388pubmed:ownerNLMlld:pubmed
pubmed-article:1800388pubmed:authorsCompleteYlld:pubmed
pubmed-article:1800388pubmed:pagination425-30lld:pubmed
pubmed-article:1800388pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1800388pubmed:meshHeadingpubmed-meshheading:1800388-...lld:pubmed
pubmed-article:1800388pubmed:meshHeadingpubmed-meshheading:1800388-...lld:pubmed
pubmed-article:1800388pubmed:meshHeadingpubmed-meshheading:1800388-...lld:pubmed
pubmed-article:1800388pubmed:meshHeadingpubmed-meshheading:1800388-...lld:pubmed
pubmed-article:1800388pubmed:meshHeadingpubmed-meshheading:1800388-...lld:pubmed
pubmed-article:1800388pubmed:meshHeadingpubmed-meshheading:1800388-...lld:pubmed
pubmed-article:1800388pubmed:meshHeadingpubmed-meshheading:1800388-...lld:pubmed
pubmed-article:1800388pubmed:meshHeadingpubmed-meshheading:1800388-...lld:pubmed
pubmed-article:1800388pubmed:meshHeadingpubmed-meshheading:1800388-...lld:pubmed
pubmed-article:1800388pubmed:meshHeadingpubmed-meshheading:1800388-...lld:pubmed
pubmed-article:1800388pubmed:meshHeadingpubmed-meshheading:1800388-...lld:pubmed
pubmed-article:1800388pubmed:meshHeadingpubmed-meshheading:1800388-...lld:pubmed
pubmed-article:1800388pubmed:meshHeadingpubmed-meshheading:1800388-...lld:pubmed
pubmed-article:1800388pubmed:meshHeadingpubmed-meshheading:1800388-...lld:pubmed
pubmed-article:1800388pubmed:year1991lld:pubmed
pubmed-article:1800388pubmed:articleTitleTransdermal monotherapy with mepindolol BIO TSD in patients with stable angina pectoris. Placebo-controlled, crossover investigation of a new therapeutic concept with 12-hours overnight application.lld:pubmed
pubmed-article:1800388pubmed:affiliationInt. Medicine Dept., St. Elisabeth Spital, Vienna, Austria.lld:pubmed
pubmed-article:1800388pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1800388pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:1800388pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:1800388pubmed:publicationTypeRandomized Controlled Triallld:pubmed